可靠股份管理层矛盾激化 董事鲍佳243万高薪事件成争论焦点

Core Viewpoint - The conflict between the chairman Jin Liwei and director Bao Jia of Kexin Co., Ltd. has intensified, leading to the dismissal of independent director Jing Naiquan, raising concerns about the independence of the board [1][5][9] Group 1: Board Decisions and Voting - On February 23, Kexin Co. announced the dismissal of independent director Jing Naiquan, with 5 out of 7 board members voting in favor and 2 (Bao Jia and Jing Naiquan) voting against [2][3] - The company stated that Jing Naiquan lost his independence and failed to fulfill his duties as an independent director [2][5] Group 2: Reasons for Dismissal - The core reason for Jing Naiquan's dismissal was his alleged "collapse of independence" regarding matters involving Bao Jia's high salary, which Kexin Co. claims undermined the decision-making process [5][6] - Bao Jia argued that Jing Naiquan maintained independent judgment and that the dismissal was retaliation from Jin Liwei for his principled stance [4][5] Group 3: Salary Dispute - The central issue of contention is Bao Jia's reported salary of 2.43 million yuan for 2024, which he claims is justified and supported by arbitration records [7][9] - Kexin Co. contends that Bao Jia's high salary is inappropriate, especially since he did not work for the company in 2025, and that the company was misled into believing it was under "arbitration pressure" to pay [9] Group 4: Regulatory Concerns - A company secretary suggested that the Zhejiang Securities Regulatory Bureau conduct a special investigation into Kexin Co.'s related party transactions and the performance of independent directors, emphasizing the need for improved governance and oversight [1][9]

Coco Healthcare-可靠股份管理层矛盾激化 董事鲍佳243万高薪事件成争论焦点 - Reportify